Hiroto Hatakeyama
Overview
Explore the profile of Hiroto Hatakeyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Suzuoki M, Tanaka H, Sakurai Y, Hatakeyama H, Akita H
Biol Pharm Bull
. 2024 Mar;
47(3):698-707.
PMID: 38538323
RNA vaccines based on Lipid nanoparticles (LNP) were put into practical use within only one year after the global outbreak of the coronavirus disease 2019 (COVID-19). This success of RNA...
2.
Anindita J, Tanaka H, Yamakawa T, Sato Y, Matsumoto C, Ishizaki K, et al.
Pharmaceutics
. 2024 Feb;
16(2).
PMID: 38399242
RNA vaccines are applicable to the treatment of various infectious diseases via the inducement of robust immune responses against target antigens by expressing antigen proteins in the human body. The...
3.
Soejima Y, Yoshioka H, Guro S, Sato H, Hatakeyama H, Sato Y, et al.
Front Cardiovasc Med
. 2024 Feb;
11:1330235.
PMID: 38361589
Background: The aim of this study was to identify significant factors affecting the effectiveness of exercise training using information of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of...
4.
Anindita J, Tanaka H, Oyama R, Hagiwara S, Shirane D, Taneichi S, et al.
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38140043
Because of its efficient and robust gene transfer capability, messenger RNA (mRNA) has become a promising tool in various research fields. The lipid nanoparticle (LNP) is considered to be a...
5.
Doi M, Tanaka H, Ohoto T, Miura N, Sakurai Y, Hatakeyama H, et al.
Small
. 2023 Jan;
19(16):e2205131.
PMID: 36703512
The reactivation of anticancer immunity is a fundamental principle in cancer immunotherapy as evidenced by the use of immune checkpoint inhibitors (ICIs). While treatment with the ICIs is shown to...
6.
Arai T, Kokubo T, Tang R, Abo H, Terui A, Hirakawa J, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36543377
Background: With the increased use of immune checkpoint inhibitors (ICIs), side effects and toxicity are a great concern. Anaphylaxis has been identified as a potential adverse event induced by ICIs....
7.
Gomi M, Sakurai Y, Sato M, Tanaka H, Miyatake Y, Fujiwara K, et al.
Adv Healthc Mater
. 2022 Dec;
12(9):e2202528.
PMID: 36535635
Lipid nanoparticles (LNPs) are one of the most successful technologies in messenger RNA (mRNA) delivery. While the liver is the most frequent target for LNP delivery of mRNA, technologies for...
8.
Yamamoto M, Kurino T, Matsuda R, Jones H, Nakamura Y, Kanamori T, et al.
J Control Release
. 2022 Oct;
352:328-337.
PMID: 36280153
Chemotherapy for peritoneal dissemination is poorly effective owing to limited drug transfer from the blood to the intraperitoneal (i.p.) compartment after intravenous (i.v.) administration. i.p. chemotherapy has been investigated to...
9.
Tanaka A, Honda T, Yasue M, Yamazaki R, Hatakeyama H, Hisaka A, et al.
J Pharmacol Sci
. 2022 Aug;
150(1):1-8.
PMID: 35926944
Ceramide, a central molecule of sphingolipid metabolism, is phosphorylated to ceramide-1-phosphate (C1P) by ceramide kinase (CerK). The CerK/C1P pathway regulates many cellular functions, but its roles in immune/inflammation-related (IIR) diseases...
10.
Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, et al.
J Control Release
. 2022 Mar;
345:200-213.
PMID: 35307507
Since the effect of cancer immunotherapy is largely dependent on the status of the immune system in the tumor microenvironment (TME), choice of therapy and the development of new therapies...